PTO/SB/21 (02-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** TBA Filing Date TRANSMITTAL 4/02/2004 **FORM** First Named Inventor Shuster Art Unit TBA (to be used for all correspondence after initial filing) Examiner Name TBA **Attorney Docket Number** 4 AH06021US01 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance communication Drawing(s) Fee Transmittal Form Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to Group Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information **Provisional Application** After Final Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer **Extension of Time Request** Identify below): Request for Refund **Express Abandonment Request** References (9 documents); Post Card CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Individual name Robert J. Lipka; Reg. 42,80) Signature Date June 16, 2004


## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name Robert J. Lipka Date Signature June 16, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



N THE UNITED STATES PATENT AND TRADEMARK OFFICE

′-----X

In re Application of:

Shuster, et al.

Patent For: COMPOSITIONS AND

METHOD FOR TREATING

MICROBIAL AND PARASITIC

INFECTIONS IN CATTLE AND

OTHER ANIMALS : Group Art Unit: TBA

Serial No.: tba

Filed: 4/2/04 ::

----X

Commissioner, Patents

P.O. Box 1450

Alexandria, Va. 22313-1450

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the applicant's duty of disclosure expressed in 37 C.F.R. § 1.56, the Examiner's attention is directed to the accompanying form PTO-1449. As no Office Action has been received to date, it is not believed that any fee is due.

The listed documents may be relevant to examination of the application. Inclusion of the document is <u>not</u> an admission that the document is prior art with respect to the invention of the application and is <u>not</u> to be construed as an admission that anything in the document renders any claim of the application unpatentable. The Examiner is requested to disregard any underlining or marginal notation (if any) appearing in a copy, since marking may have been done for another purpose and not pertain in any manner to the subject application.

## AH06021US 01

Copies of the listed documents are enclosed.

Applicants assert that the claimed invention is patentable over the documents listed on PTO-1449.

Consideration of the documents, and the return of an initialed copy of the duplicate copy of the enclosed forms PTO-1449 to indicate such consideration, are respectfully requested.

Should the Office have any questions or concerns, please do not hesitate to contact the undersigned at the Examiner's convenience.

Patent Department, K-6-1, 1990 SCHERING-PLOUGH CORPORATION 2000 Galloping Hill Road Kenilworth, New Jersey 07033-0530 Respectfully submitted,

Robert J. Lipka
Attorney for Applicant(s)
Registration No.: 42,807

Telephone No.: (908) 298-5056 Facsimile No. (908) 298-5388

Sheet	1	of	1

.(							Sheet _	<u>1</u> of _	_1_			
FORM RIPO		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO.: AH06021US 01		Application Serial No. TBA					
INFORMATION DISCLOSURE STATE BY APPLICANT			ATEMENT	APPLICANT: Shuster et al.								
(Use several sheets if necessa			ary) FILING DATE		: GROUP: TBA							
			U.S. P.	ATENT DOCU	MENTS	· · · · · ·						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAM	/E	CLASS		FILING APPRO	PRIATE			
	AA	6,653,288	11/25/03	Beuvry		514		09/30/0				
	AB	6,174,540	1/16/01	Williams		424		9/14/98				
	AC	5,733,566	3/31/98	Lewis		424		10/30/9				
	AD	US2003/0064939 A1	4/03/03	Sklavounos		514		4/25/02				
	AE											
	AF					ļ						
	AG											
	AH							<u> </u>				
	Al		ļ			ļ		ļ				
	AJ						<u> </u>					
•	AK			<u> </u>		<u> </u>		L				
		F	OREIGN	PATENT DOC	CUMENTS							
		DOCUMENT	DATE	COUNTRY		CLASS	SUB-	TRANS	LATION			
		NUMBER					CLASS	YES	NO			
	AL	WO02/088158	4/07/02	PCT					X			
	АМ	EP1078631	2/28/01	EP					X			
	AN											
•	AO		,									
.3	AP											
	ОТ	HER DOCUMENT	S (Includ	ling Author, Titl	e, Date, Pert	inent Pa	iges, Et	c.)				
	AQ	Letavic, et al., "Synthesis and Activity of a Novel Class of Tribasic Macrocyclic Antibiotics: The Triamilides", Bioorganic and Medicinal Chemistry Letters, 12, pp. 2771-2774 (2002).										
	AR	Nowakowski, et al., "Pharmacokinetic Profiles of some Triamilides, a new class of macrolide, in mice and cattle", J. Vet. Pharmacol. Therap. 26, 82-307 (2003).										
	AS	Bronk, et al., "Synthesis, Stereochemical Assignment and Biological Activity of a Novel Series of C-4 Modified Aza-Macrolides", Bioorganic & Medicinal Chemistry Letters, 1955 – 1958 (2003).										
	AT	Wiodified Aza-Wacion	ides , Dioor	game & Medicinal C	memistry Letters	, 1733 — 1	<i>730</i> (2003	<i>)</i> ·				
	ΑÜ											
	AV											
EXAMINE		1		DATE C	ONSIDERED							

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.